data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
SPY
––%
QQQ
––%
BTC/USD
––%
DIA
––%
GLD
––%
TLT
––%
Nektar Therapeutics
(NASDAQ:NKTR)
$2.88
At close: Dec 1(Delayed 15-Minutes)
Get Real Time Here
$2.88
PreMarket: 4:02PM EDT
Day Range- - -52 Wk Range2.73 - 15.95Open / Close- / -Float / Outstanding122.7M / 188M
Vol / Avg.- / 1.8MMkt Cap541.3MP/E-50d Avg. Price3.47
Div / Yield-Payout Ratio-Total Float122.7MEPS-0.31

Nektar Therapeutics Stock (NASDAQ:NKTR), Quotes and News Summary

Nektar Therapeutics Stock (NASDAQ: NKTR) stock price, news, charts, stock research, profile.

Day Range- - -52 Wk Range2.73 - 15.95Open / Close- / -Float / Outstanding122.7M / 188M
Vol / Avg.- / 1.8MMkt Cap541.3MP/E-50d Avg. Price3.47
Div / Yield-Payout Ratio-Total Float122.7MEPS-0.31
PRNewswire - Nov 10, 2022, 9:05AM
PRNewswire - Nov 9, 2022, 9:00AM
PRNewswire - Nov 3, 2022, 4:15PM
PRNewswire - Oct 25, 2022, 6:00PM
PRNewswire - Oct 19, 2022, 1:06PM
PRNewswire - Sep 7, 2022, 1:15AM
PRNewswire - Aug 16, 2022, 8:30AM
PRNewswire - Aug 4, 2022, 4:15PM
PRNewswire - Jul 26, 2022, 6:00PM
PRNewswire - Jul 1, 2022, 6:30AM
Business Wire - May 11, 2022, 8:01AM
PRNewswire - May 5, 2022, 4:15PM
Business Wire - Apr 29, 2022, 6:59AM
PRNewswire - Apr 28, 2022, 4:01PM
PRNewswire - Apr 25, 2022, 4:30PM
PRNewswire - Apr 23, 2022, 5:30PM
PRNewswire - Apr 22, 2022, 8:30AM
PRNewswire - Apr 18, 2022, 11:01AM
PRNewswire - Apr 14, 2022, 4:30PM
PRNewswire - Mar 26, 2022, 12:37AM
Newsfile - Mar 23, 2022, 3:00PM
ACCESSWIRE - Mar 18, 2022, 7:30PM
PRNewswire - Mar 16, 2022, 8:31PM
ACCESSWIRE - Mar 15, 2022, 11:10AM
Newsfile - Mar 15, 2022, 10:55AM
PRNewswire - Mar 14, 2022, 7:05AM
Business Wire - Mar 14, 2022, 6:59AM
PRNewswire - Feb 28, 2022, 4:15PM
PRNewswire - Feb 17, 2022, 6:00PM
PRNewswire - Jan 5, 2022, 9:00AM
PRNewswire - Dec 21, 2021, 11:18AM
PRNewswire - Dec 15, 2021, 9:10AM
Business Wire - Dec 15, 2021, 8:00AM
PRNewswire - Dec 13, 2021, 9:00AM
PRNewswire - Dec 10, 2021, 8:45AM
Seeking Alpha - Nov 18, 2022, 5:50PM
TipRanks - Nov 17, 2022, 4:15AM
TipRanks - Nov 9, 2022, 11:27PM
InvestorsObserver - Nov 4, 2022, 3:00PM
Seeking Alpha - Nov 3, 2022, 11:15PM
TipRanks - Nov 3, 2022, 11:10PM
Seeking Alpha - Nov 2, 2022, 5:35PM
InvestorsObserver - Oct 27, 2022, 1:29PM
TipRanks - Oct 11, 2022, 7:15AM
TipRanks - Oct 11, 2022, 4:20AM
InvestorsObserver - Oct 7, 2022, 12:33PM
Seeking Alpha - Oct 7, 2022, 10:02AM
Seeking Alpha - Oct 7, 2022, 9:12AM
TipRanks - Oct 7, 2022, 6:33AM
TipRanks - Oct 7, 2022, 6:33AM
InvestorsObserver - Sep 26, 2022, 3:45PM
InvestorsObserver - Sep 22, 2022, 3:40PM
InvestorsObserver - Sep 14, 2022, 12:15PM
TipRanks - Sep 11, 2022, 2:15AM
TipRanks - Sep 7, 2022, 8:23AM
TipRanks - Sep 5, 2022, 8:23AM
TipRanks - Aug 31, 2022, 8:21AM
InvestorsObserver - Aug 30, 2022, 3:02PM
TipRanks - Aug 29, 2022, 8:21AM
TipRanks - Aug 16, 2022, 8:11AM
TipRanks - Aug 11, 2022, 10:11PM
TipRanks - Aug 4, 2022, 11:49PM
Seeking Alpha - Aug 3, 2022, 5:35PM
Seeking Alpha - Jul 17, 2022, 12:51PM
InvestorsObserver - Jul 14, 2022, 12:16PM
InvestorsObserver - Jul 12, 2022, 12:11PM
TipRanks - Jul 11, 2022, 7:55PM
TipRanks - Jul 1, 2022, 9:35AM
TipRanks - May 31, 2022, 9:05AM
InvestorsObserver - May 23, 2022, 2:54PM
Sector: Health Care.Industry: Pharmaceuticals
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Read More

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-02-27
REV
Q3 2022Est.ActualSurprise
EPS-0.450-0.310 0.1400
REV22.610M23.625M1.015M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Nektar Therapeutics (NKTR) stock?

A

You can purchase shares of Nektar Therapeutics (NASDAQ: NKTR) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Nektar Therapeutics's (NKTR) competitors?

Q

What is the target price for Nektar Therapeutics (NKTR) stock?

A

The latest price target for Nektar Therapeutics (NASDAQ: NKTR) was reported by JP Morgan on Monday, August 8, 2022. The analyst firm set a price target for 0.00 expecting NKTR to fall to within 12 months (a possible -100.00% downside). 12 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Nektar Therapeutics (NKTR)?

A

The stock price for Nektar Therapeutics (NASDAQ: NKTR) is $2.88 last updated December 1, 2022, 9:00 PM UTC.

Q

Does Nektar Therapeutics (NKTR) pay a dividend?

A

There are no upcoming dividends for Nektar Therapeutics.

Q

When is Nektar Therapeutics (NASDAQ:NKTR) reporting earnings?

A

Nektar Therapeutics’s Q4 earnings are confirmed for Monday, February 27, 2023.

Q

Is Nektar Therapeutics (NKTR) going to split?

A

There is no upcoming split for Nektar Therapeutics.

Q

What sector and industry does Nektar Therapeutics (NKTR) operate in?

A

Nektar Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.